A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma

Trial Profile

A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2016

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis; Novartis Pharma A.G.
  • Most Recent Events

    • 30 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 06 Oct 2014 Planned End Date changed from 1 Dec 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.
    • 06 Oct 2014 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top